JUBLPHARMA.NS Profit & Loss
Jubilant Pharmova Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 8 years on file
(FY2017-18 to FY2025-26)
· fetched 2026-08-23 23:33
| Line item | FY2017-18 | FY2019-20 | FY2020-21 standalone basis | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7,464.75 Cr. | ₹9,154.41 Cr. | ₹2,709.50 Cr. | ₹6,059.17 Cr. | ₹6,281.73 Cr. | ₹6,702.90 Cr. | ₹7,234.50 Cr. | ₹8,279.60 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹7,557.81 Cr. | ₹9,154.41 Cr. | ₹2,709.50 Cr. | ₹6,130.16 Cr. | ₹6,281.73 Cr. | ₹6,702.90 Cr. | ₹7,234.50 Cr. | ₹8,279.60 Cr. | SegmentRevenueFromOperations |
| Other Income | ₹133.09 Cr. | ₹47.43 Cr. | ₹47.88 Cr. | ₹82.28 Cr. | ₹38.33 Cr. | ₹68.70 Cr. | ₹56.80 Cr. | ₹66.00 Cr. | OtherIncome |
| Total Income | ₹7,597.84 Cr. | ₹9,201.84 Cr. | ₹2,757.38 Cr. | ₹6,141.45 Cr. | ₹6,320.06 Cr. | ₹6,771.60 Cr. | ₹7,291.30 Cr. | ₹8,345.60 Cr. | Income |
| Cost of Materials Consumed | ₹2,678.15 Cr. | ₹3,119.42 Cr. | ₹1,328.92 Cr. | ₹1,348.70 Cr. | ₹1,666.41 Cr. | ₹1,821.30 Cr. | ₹1,985.30 Cr. | ₹2,320.30 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹242.82 Cr. | ₹276.58 Cr. | ₹66.23 Cr. | ₹201.62 Cr. | ₹252.22 Cr. | ₹241.20 Cr. | ₹297.10 Cr. | ₹313.10 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-52.20 Cr. | ₹-255.43 Cr. | ₹55.21 Cr. | ₹-62.32 Cr. | ₹-40.70 Cr. | ₹78.20 Cr. | ₹34.60 Cr. | ₹10.90 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1,555.88 Cr. | ₹2,127.68 Cr. | ₹220.67 Cr. | ₹2,043.39 Cr. | ₹2,166.02 Cr. | ₹2,216.00 Cr. | ₹2,267.90 Cr. | ₹2,700.60 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹284.28 Cr. | ₹287.41 Cr. | ₹101.80 Cr. | ₹145.49 Cr. | ₹188.20 Cr. | ₹272.30 Cr. | ₹240.30 Cr. | ₹211.80 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹415.05 Cr. | ₹461.93 Cr. | ₹99.97 Cr. | ₹381.70 Cr. | ₹554.03 Cr. | ₹381.90 Cr. | ₹368.60 Cr. | ₹440.40 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹1,614.78 Cr. | ₹1,939.08 Cr. | ₹611.41 Cr. | ₹1,442.44 Cr. | ₹1,461.53 Cr. | ₹1,445.40 Cr. | ₹1,475.90 Cr. | ₹1,674.90 Cr. | OtherExpenses |
| Total Expenses | ₹6,738.76 Cr. | ₹7,956.67 Cr. | ₹2,484.21 Cr. | ₹5,501.02 Cr. | ₹6,247.71 Cr. | ₹6,456.30 Cr. | ₹6,669.70 Cr. | ₹7,672.00 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹859.08 Cr. | ₹1,245.17 Cr. | ₹273.17 Cr. | ₹640.43 Cr. | ₹72.35 Cr. | ₹315.30 Cr. | ₹621.60 Cr. | ₹673.60 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹-34.64 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-56.82 Cr. | ₹-168.90 Cr. | ₹359.50 Cr. | ₹-59.20 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹859.08 Cr. | ₹1,210.53 Cr. | ₹273.17 Cr. | ₹640.43 Cr. | ₹15.53 Cr. | ₹146.40 Cr. | ₹981.10 Cr. | ₹614.40 Cr. | ProfitBeforeTax |
| Tax Expense | ₹224.66 Cr. | ₹312.29 Cr. | ₹58.69 Cr. | ₹217.43 Cr. | ₹92.66 Cr. | ₹97.80 Cr. | ₹144.30 Cr. | ₹216.60 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹634.42 Cr. | ₹898.24 Cr. | ₹214.48 Cr. | ₹413.02 Cr. | ₹-64.88 Cr. | ₹72.70 Cr. | ₹836.30 Cr. | ₹397.50 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹0.00 Cr. | ₹898.24 Cr. | N/A | ₹413.94 Cr. | ₹-60.98 Cr. | ₹77.10 Cr. | ₹839.40 Cr. | ₹398.50 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹41.25 | ₹56.39 | ₹13.47 | ₹26.00 | ₹-3.83 | ₹4.87 | ₹52.99 | ₹25.15 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹41.25 | ₹56.39 | ₹13.47 | ₹26.00 | ₹-3.83 | ₹4.86 | ₹52.85 | ₹25.08 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from JUBLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).